Abstract
Since the 1950s, herpes simplex viruses (HSV) have played prominent roles in the development of antivirals. The first efficacious antivirals, as well as the first safe for systemic use, were developed against HSV. It was only in 1995 when the first antiviral against a target not validated first with HSV was approved for clinical use (sequinavir). The early successes of targeting HSV DNA replication were most influential in developing the concept that antiviral drugs must target viral proteins. Such concept has ensured the safety of current antiviral drugs, which all target viral proteins. Current antivirals have proven to have no major negative effects on non-infected cells or treated patients. Because of their success widespread and use, however, these drugs have been found to have some limitations. Perhaps the clinically most important one is their ability to promptly select for drug-resistant viral strains. Owing to such limitations, cellular proteins are now considered as valid targets for novel antiviral drugs. The discovery that pharmacological CDK inhibitors (PCIs) inhibit HSV replication through novel mechanisms played a major role in this new appreciation of cellular proteins as potential targets for antivirals. This appreciation is reflected in the scheduling of PCIs to enter clinical trials as antivirals (against HIV). Herein, we will review the roles of HSV as model viruses in the discovery and development of antiviral drugs. The major focus will be on the recent discovery on the activities of PCIs against HSV and other viruses.
Keywords: helicase-primase, transcription, roscovitine, PCI, CDK, HSV, Antivirals
Current Pharmaceutical Design
Title: Herpes Simplex Viruses in Antiviral Drug Discovery
Volume: 12 Issue: 11
Author(s): Luis M. Schang
Affiliation:
Keywords: helicase-primase, transcription, roscovitine, PCI, CDK, HSV, Antivirals
Abstract: Since the 1950s, herpes simplex viruses (HSV) have played prominent roles in the development of antivirals. The first efficacious antivirals, as well as the first safe for systemic use, were developed against HSV. It was only in 1995 when the first antiviral against a target not validated first with HSV was approved for clinical use (sequinavir). The early successes of targeting HSV DNA replication were most influential in developing the concept that antiviral drugs must target viral proteins. Such concept has ensured the safety of current antiviral drugs, which all target viral proteins. Current antivirals have proven to have no major negative effects on non-infected cells or treated patients. Because of their success widespread and use, however, these drugs have been found to have some limitations. Perhaps the clinically most important one is their ability to promptly select for drug-resistant viral strains. Owing to such limitations, cellular proteins are now considered as valid targets for novel antiviral drugs. The discovery that pharmacological CDK inhibitors (PCIs) inhibit HSV replication through novel mechanisms played a major role in this new appreciation of cellular proteins as potential targets for antivirals. This appreciation is reflected in the scheduling of PCIs to enter clinical trials as antivirals (against HIV). Herein, we will review the roles of HSV as model viruses in the discovery and development of antiviral drugs. The major focus will be on the recent discovery on the activities of PCIs against HSV and other viruses.
Export Options
About this article
Cite this article as:
Schang M. Luis, Herpes Simplex Viruses in Antiviral Drug Discovery, Current Pharmaceutical Design 2006; 12 (11) . https://dx.doi.org/10.2174/138161206776361174
DOI https://dx.doi.org/10.2174/138161206776361174 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Modulation of Calcium Signaling in Glioblastoma Multiforme: A Therapeutic Promise for Natural Products
Mini-Reviews in Medicinal Chemistry CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy Colchicine in Neurosurgery
Current Pharmaceutical Design Akt Pathway Inhibitors
Current Topics in Medicinal Chemistry Tapasin and Human Leukocyte Antigen Class I Dysregulation Correlates with Survival in Glioblastoma Multiforme
Anti-Cancer Agents in Medicinal Chemistry Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Green Chemistry Starting from 2H-Pyran-2-one Derivatives
Current Green Chemistry Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews G Protein-Coupled Receptor Fusion Proteins in Drug Discovery
Current Pharmaceutical Design Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy
Current Topics in Medicinal Chemistry Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry